Ono Pharmaceutical Co., Ltd. (4528)

Name: Ono Pharmaceutical Co., Ltd. (4528) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-10-02

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia.

Cifras clave

Capitalización bursátil: JPY 1.08 trillion
Ingresos (ejercicio cerrado en 2026-03-31): JPY 515.8B
Beneficio neto: JPY 69.8B
Margen bruto: 72.5%
Margen neto: 13.5%

Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Ingresos totales	JPY 515.8B	JPY 486.9B	JPY 502.7B	JPY 447.2B
Beneficio bruto	JPY 374.1B	JPY 338.9B	JPY 375.5B	JPY 337.1B
Ingresos operativos (EBIT)	JPY 92.2B	JPY 59.7B	JPY 159.9B	JPY 142.0B
Ingresos netos	JPY 69.8B	JPY 50.0B	JPY 128.0B	JPY 112.7B

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de 4528. /companies/us/4528

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.